CORE Biomedicine Innovates with UTokyo IPC Investment
Deal News | Mar 14, 2025 | UTokyo Innovation Platform Co
UTokyo Innovation Platform Co., Ltd. (UTokyo IPC) has made a significant investment in CORE Biomedicine, Inc., a biotech startup based in Cambridge, Massachusetts, focused on developing oncology drugs. This investment is part of their Accelerating Open Innovation 1 Investment Limited Partnership (AOI Fund I), which was launched in 2020 to foster open innovation activities centered around the University of Tokyo. The fund seeks to nurture and invest in startups through collaborations with industry leaders and academia. CORE Biomedicine aims to advance innovative therapeutics, leveraging research from leading institutions, and UTokyo IPC's backing is expected to aid in achieving this goal while enhancing global biotech innovation.
Sectors
- Biotechnology
- Investment Fund Management
Geography
- Japan – UTokyo IPC is based in Japan and manages funds supporting global innovation.
- United States – CORE Biomedicine, the startup invested in by UTokyo IPC, is based in Cambridge, Massachusetts.
Industry
- Biotechnology – CORE Biomedicine operates in the biotech sector, focusing on oncology drug development.
- Investment Fund Management – UTokyo IPC manages investment funds aimed at fostering startups through open innovation.
Financials
- Not disclosed – The financial details regarding the investment in CORE Biomedicine were not disclosed in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| UTokyo Innovation Platform Co., Ltd. (UTokyo IPC) | Investing Company | Company | An investment company dedicated to advancing the academic startup ecosystem. |
| CORE Biomedicine, Inc. | Target Company | Company | A biotech startup focused on oncology drug development. |
| Kosuke Ueda | President & CEO of UTokyo IPC | Person | President & CEO of UTokyo IPC, the entity making the investment. |
| Ping Zhu, Ph.D. | CEO of CORE Biomedicine | Person | CEO of CORE Biomedicine, the biotech company receiving investment. |
| Makoto (Mark) Ohori, Ph.D. | Partner and Chief Investment Officer, Life Sciences at UTokyo IPC | Person | Partner and Chief Investment Officer for Life Sciences at UTokyo IPC. |